Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:ASRT NASDAQ:CASI NASDAQ:CLSD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$2.78-3.5%$2.53$1.60▼$15.65$75.26M1.65409,643 shs83,094 shsASRTAssertio$0.67+0.4%$0.66$0.51▼$1.70$64.46M0.29519,184 shs196,154 shsCASICASI Pharmaceuticals$1.26-2.3%$1.60$1.09▼$7.67$15.50M0.5348,193 shs15,904 shsCLSDClearside Biomedical$0.41-31.9%$0.81$0.32▼$1.65$31.78M2.05390,967 shs3.61 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience0.00%+6.72%+23.01%+23.83%-82.93%ASRTAssertio0.00%-2.60%+2.11%+10.26%-59.46%CASICASI Pharmaceuticals0.00%-10.00%-7.35%-37.62%-79.97%CLSDClearside Biomedical0.00%-53.67%-48.10%-52.33%-66.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANROAlto Neuroscience1.9655 of 5 stars3.33.00.00.00.00.81.3ASRTAssertio1.8651 of 5 stars3.50.00.00.02.10.81.3CASICASI Pharmaceuticals3.7095 of 5 stars3.53.00.04.30.61.70.0CLSDClearside Biomedical2.1096 of 5 stars4.13.00.00.01.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.57Moderate Buy$8.50205.76% UpsideASRTAssertio 3.00Buy$2.75308.62% UpsideCASICASI Pharmaceuticals 3.00Buy$4.00217.46% UpsideCLSDClearside Biomedical 2.17Hold$4.20924.39% UpsideCurrent Analyst Ratings BreakdownLatest CASI, ANRO, CLSD, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$2.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$3.006/26/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.005/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/19/2025CASICASI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/16/2025CLSDClearside BiomedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.005/15/2025ANROAlto NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/AASRTAssertio$124.96M0.52$0.05 per share13.71$1.27 per share0.53CASICASI Pharmaceuticals$28.54M0.54N/AN/A$0.12 per share10.50CLSDClearside Biomedical$1.66M19.19N/AN/A($0.51) per share-0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$61.43M-$2.34N/AN/AN/AN/A-39.35%-33.86%8/12/2025 (Estimated)ASRTAssertio-$21.58M-$0.32N/A22.43N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)CASICASI Pharmaceuticals-$39.26M-$2.55N/A∞N/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)CLSDClearside Biomedical-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)Latest CASI, ANRO, CLSD, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025N/ACASICASI Pharmaceuticals-$0.47N/AN/AN/A$6.28 millionN/A8/12/2025Q2 2025ANROAlto Neuroscience-$0.57N/AN/AN/AN/AN/A8/11/2025Q2 2025CLSDClearside Biomedical-$0.12N/AN/AN/A$0.50 millionN/A8/6/2025Q2 2025ASRTAssertio-$0.06N/AN/AN/A$27.86 millionN/A5/16/2025Q1 2025CASICASI Pharmaceuticals-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million5/13/2025Q1 2025ANROAlto Neuroscience-$0.59-$0.53+$0.06-$0.56N/AN/A5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AASRTAssertioN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1522.5322.53ASRTAssertio0.361.661.35CASICASI PharmaceuticalsN/A0.810.68CLSDClearside BiomedicalN/A3.193.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AASRTAssertio48.96%CASICASI Pharmaceuticals22.23%CLSDClearside Biomedical18.75%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.13%ASRTAssertio4.00%CASICASI Pharmaceuticals21.24%CLSDClearside Biomedical6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.07 million24.06 millionN/AASRTAssertio2095.78 million91.95 millionOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableCLSDClearside Biomedical3077.71 million72.89 millionOptionableCASI, ANRO, CLSD, and ASRT HeadlinesRecent News About These CompaniesHC Wainwright & Co. Downgrades Clearside Biomedical (CLSD)1 hour ago | msn.comClearside Biomedical Insider Trading Activity | NASDAQ:CLSD | BenzingaJuly 18 at 8:35 PM | benzinga.comChardan Capital Downgrades Clearside Biomedical (CLSD)July 18 at 8:35 PM | msn.comThis Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayJuly 18 at 3:35 PM | benzinga.comClearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic AlternativesJuly 18 at 3:35 PM | marketwatch.comNeedham Downgrades Clearside Biomedical (CLSD)July 18 at 10:34 AM | msn.comClearside Biomedical (NASDAQ:CLSD) Lowered to "Neutral" Rating by Chardan CapitalJuly 18 at 8:50 AM | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Stock Rating Lowered by Stifel NicolausJuly 18 at 8:50 AM | marketbeat.comClearside Biomedical stock falls after announcing strategic alternatives explorationJuly 17 at 5:14 PM | in.investing.comClearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology PipelineJuly 17 at 7:05 AM | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Shares Up 0.3% - Here's What HappenedJuly 7, 2025 | marketbeat.comShareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested five years agoJune 28, 2025 | finance.yahoo.comClearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit MeetingJune 17, 2025 | globenewswire.comClearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should KnowMay 29, 2025 | zacks.comClearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology ForumMay 21, 2025 | globenewswire.comClearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comClearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.com7CLSD : A Peek at Clearside Biomedical's Future EarningsMay 14, 2025 | benzinga.comClearside Biomedical Q1 2025 Earnings PreviewMay 14, 2025 | msn.comClearside Biomedical at The Citizens Conference: Strategic Trial InsightsMay 9, 2025 | investing.comClearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMay 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAstera Labs: AI Infrastructure Play With Significant Growth AheadBy Nathan Reiff | June 26, 2025View Astera Labs: AI Infrastructure Play With Significant Growth AheadCASI, ANRO, CLSD, and ASRT Company DescriptionsAlto Neuroscience NYSE:ANRO$2.78 -0.10 (-3.47%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$2.77 -0.01 (-0.36%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Assertio NASDAQ:ASRT$0.67 +0.00 (+0.45%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.59%) As of 07/18/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.CASI Pharmaceuticals NASDAQ:CASI$1.26 -0.03 (-2.33%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$1.27 +0.01 (+0.48%) As of 07/18/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Clearside Biomedical NASDAQ:CLSD$0.41 -0.19 (-31.87%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+1.95%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.